Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

This study has been terminated.
(Slow recruitment. No safety concerns during this study.)
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by:
European Group for Blood and Marrow Transplantation
ClinicalTrials.gov Identifier:
NCT00895297
First received: May 6, 2009
Last updated: December 6, 2011
Last verified: December 2011
  Purpose

This is a phase II efficacy (indicates the capacity for beneficial change or therapeutic effect) and safety study of Dasatinib in patients with relapsed Chronic Myeloid Leukemia (CML) following a Stem Cell Transplant (SCT) and who are not benefiting from other treatment, such as imatinib therapy.

A relapse is when an illness that has seemed to be getting better, or to have been cured, comes back or gets worse again.

A total of 50 patients ≥18 years of age will be registered on the trial.


Condition Intervention Phase
Chronic Myeloid Leukemia
Drug: Dasatinib (Sprycel)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation

Resource links provided by NLM:


Further study details as provided by European Group for Blood and Marrow Transplantation:

Primary Outcome Measures:
  • CMR as determined by two consecutive (-) RT-PCR tests for the presence of BCR-ABL transcripts in peripheral blood samples 1 year after starting Dasatinib therapy. The expected CMR of >30% would be regarded as being clinically relevant [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Complete haematological response (CHR) at 3 months post commencing Dasatinib for those that have relapsed at the haematological level. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Complete cytogenetic response (CCyR) at 6 and 12 months post commencing Dasatinib for those that have relapsed at the cytogenetic level. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Major molecular response (MMR) at 12 months post commencing Dasatinib for all patients. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Proportion of patients requiring DLI during the first 12 months [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Overall survival (OS) - Limited to 3 years. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Progression free survival (PFS). [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • Adverse event (AE) rate. [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Rate of dose reductions, interruptions and discontinuations. [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: February 2010
Study Completion Date: November 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Dasatinib (Sprycel)
    100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
Detailed Description:

Primary Objective:

  1. To assess the efficacy of Dasatinib therapy in chronic and accelerated phase BCR-ABL (+) (Ph + and Ph -) CML patients that undergo molecular, cytogenetic or haematological relapse following SCT.

Secondary Objective(s):

  1. To assess the impact of Dasatinib therapy on patient survival after relapse post-SCT and the incidence of any subsequent need for 'rescue' DLI.
  2. To assess the safety of Dasatinib in this clinical context using this specific dose regimen

Chronic myeloid leukaemia (CML) is a form of cancer that starts in cells within the bone marrow called haematopoietic stem cells. Stem cells are immature cells which can divide many times and eventually produce all the lymphocytes and myeloid cells present in the blood. They are produced in the bone marrow - the spongy tissue found in large bones, including the pelvis, sternum, limb bones and the ribs.

Leukaemia is a cancer of the white blood cells. In CML, too many myeloid cells (one of the main types of white blood cells which defend the body against infectious diseases) are produced. The myeloid cells are released into the blood when they are immature and unable to work properly. These immature white blood cells are known as blasts.

The immature cells fill up the bone marrow and prevent it from making blood cells properly. As the leukaemia cells do not mature, they can't do the work of normal white blood cells, which leads to an increased risk of infection. Because the bone marrow is overcrowded with immature white cells it also can't make enough healthy red cells and platelets.

CML usually develops very slowly, which is why it is called 'chronic' myeloid leukaemia.

The aim of this study is to assess the efficacy (indicates the capacity for beneficial change or therapeutic effect) of a leukaemia treatment called dasatinib (sprycel) in patients with relapsed Chronic Myeloid Leukaemia (CML) following a Stem Cell Transplant (SCT) and who are not benefiting from other treatment, such as imatinib therapy.

A relapse is when an illness that has seemed to be getting better, or to have been cured, comes back or gets worse again.

Dasatinib works by blocking (inhibiting) signals within cancer cells that cause the cell to grow and divide.

The growth of cells in our bodies is controlled by signals that switch on and off within the cells. When the signals for growth are switched on the cells are triggered to grow and multiply. People with CML have an abnormal signaling protein inside their leukaemia cells. This abnormal protein sends out grow-and-divide signals to the cells at all times and never switches off.

Dasatinib finds the faulty protein and locks onto it. This prevents the protein from stimulating the cells to grow. Dasatinib is known as a signal transduction inhibitor, because it blocks the 'grow' signal. The chemical it blocks is called tyrosine kinase, so dasatinib is also known as a tyrosine kinase inhibitor.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients greater or equal to 18 years of age.
  2. Diagnosed with BCR-ABL (+) Chronic Myeloid Leukemia (they can be Philadelphia chromosome positive or negative)
  3. Prior therapy including imatinib
  4. Patients transplanted from an HLA-identical sibling or an HLA-matched unrelated donor.
  5. Patients transplanted in first chronic phase or accelerated phase.
  6. Patients with untreated relapse of BCR-ABL (+) CML (they can be Philadelphia chromosome positive or negative) after allogeneic transplantation and entered within 6 weeks of the first detection of relapse.
  7. Molecular, cytogenetic or haematological relapse in chronic or accelerated phase.
  8. Written informed consent.
  9. Absence of serious concomitant illness

Exclusion Criteria:

  1. Patients relapsing in blast crisis.
  2. Patients transplanted after blastic transformation of CML.
  3. Patients receiving any therapy for relapse other than withdrawal of immunosuppression (DLI is not permitted).
  4. Patients treated with other investigational agents during the previous 30 days
  5. Patients previously treated with Dasatinib.
  6. Absence of written informed consent.
  7. Presence of serious concomitant disease.
  8. History of a significant bleeding disorder unrelated to CML.
  9. Pregnancy or lactation status positive.
  10. SGOT and SGPT more than 2.5 x the upper limit of the normal range as determined by the laboratory where the analysis is performed.
  11. Total serum bilirubin level more than 2 x the upper limit of the normal range of the laboratory where the analysis is performed.
  12. Serum creatinine concentration more than 1.5 x the upper limit of the normal range of the laboratory where the analysis is performed.
  13. Concomitant Medications, any of the following should be considered for exclusion:

    • Category I drugs that are generally accepted to have a risk of causing Torsades de Points including: (Patients must discontinue drug 7 days prior to starting Dasatinib):
    • quinidine, procainamide, disopyramide.
    • amiodarone, sotalol, ibutilide, dofetilide.
    • erythromycin, clarithromycin.
    • chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, ziprasidone.
    • cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
    • The concomitant use of H2 blockers or proton pump inhibitors with Dasatinib is not recommended. The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving Dasatinib therapy. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of Dasatinib.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00895297

Locations
France
E Herriot Hospital
Lyon, France
Germany
University Hospital
Hamburg, Germany
Uniklinik Leipzig
Leipzig, Germany
Stiftung Deutsche Klinik für Diagnostik
Wiesbaden, Germany
Switzerland
University Hospital
Basel, Switzerland, 4031
Hopitaux Universitaires de Geneve
Geneva, Switzerland
United Kingdom
Hammersmith Hospital
London, United Kingdom, W12 0NN
Sponsors and Collaborators
European Group for Blood and Marrow Transplantation
Bristol-Myers Squibb
Investigators
Principal Investigator: Eduardo L Olavarria, Dr Hospital De Navarra Irunlarrea, Spain
  More Information

No publications provided

Responsible Party: Ruzena Uddin, EBMT
ClinicalTrials.gov Identifier: NCT00895297     History of Changes
Other Study ID Numbers: 2008-001361-29, CLWP-001-2008
Study First Received: May 6, 2009
Last Updated: December 6, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Switzerland: Swissmedic
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by European Group for Blood and Marrow Transplantation:
Relapsing after allogeneic transplantation
Dasatinib
Sprycel
Philadelphia Chromosomes

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Accelerated Phase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Dasatinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 20, 2014